We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
- Authors
DuBois, Steven G; Shusterman, Suzanne; Reid, Joel M; Ingle, Ashish M; Ahern, Charlotte H; Baruchel, Sylvain; Glade-Bender, Julia; Ivy, Percy; Adamson, Peter C; Blaney, Susan M
- Abstract
Sunitinib is an oral tyrosine kinase inhibitor of VEGF, PDGF, c-KIT, and flt-3 receptors. A pediatric phase I study of sunitinib capsules identified the maximum tolerated dose as 15 mg/m(2)/day. This study was conducted to evaluate sunitinib given as a powder formulation.
- Publication
Cancer chemotherapy and pharmacology, 2012, Vol 69, Issue 4, p1021
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-011-1798-2